Cargando…
Immunoproteasome Inhibitor–Doxorubicin Conjugates Target Multiple Myeloma Cells and Release Doxorubicin upon Low-Dose Photon Irradiation
[Image: see text] Proteasome inhibitors are established therapeutic agents for the treatment of hematological cancers, as are anthracyclines such as doxorubicin. We here present a new drug targeting approach that combines both drug classes into a single molecule. Doxorubicin was conjugated to an imm...
Autores principales: | Maurits, Elmer, van de Graaff, Michel J., Maiorana, Santina, Wander, Dennis P. A., Dekker, Patrick M., van der Zanden, Sabina Y., Florea, Bogdan I., Neefjes, Jacques J. C., Overkleeft, Herman S., van Kasteren, Sander I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181259/ https://www.ncbi.nlm.nih.gov/pubmed/32275401 http://dx.doi.org/10.1021/jacs.9b11969 |
Ejemplares similares
-
Doxorubicin and Aclarubicin: Shuffling Anthracycline
Glycans for Improved Anticancer Agents
por: Wander, Dennis P. A., et al.
Publicado: (2020) -
New insights into the activities and toxicities of the old anticancer drug doxorubicin
por: van der Zanden, Sabina Y., et al.
Publicado: (2020) -
Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors
por: Besse, Andrej, et al.
Publicado: (2022) -
Synthetic (N,N-Dimethyl)doxorubicin
Glycosyl Diastereomers to Dissect Modes of Action of Anthracycline
Anticancer Drugs
por: Wander, Dennis P. A., et al.
Publicado: (2021) -
Uncoupling DNA damage from chromatin damage to detoxify doxorubicin
por: Qiao, Xiaohang, et al.
Publicado: (2020)